Cargando…
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry
INTRODUCTION: Understanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive and palliative care. METHODS: Prognostic factors influencing overall survival (OS) and progression-free survival (PFS)...
Autores principales: | Metzenmacher, Martin, Griesinger, Frank, Hummel, Horst-Dieter, Elender, Corinna, Schäfer, Harald, de Wit, Maike, Kaiser, Ulrich, Kern, Jens, Jänicke, Martina, Spring, Lisa, Zacharias, Stefan, Kaiser-Osterhues, Anja, Groth, Annika, Hipper, Annette, Zaun, Gregor, Dörfel, Steffen, Güldenzoph, Björn, Müller, Lothar, Uhlig, Jens, Thomas, Michael, Sebastian, Martin, Eberhardt, Wilfried E.E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892864/ https://www.ncbi.nlm.nih.gov/pubmed/36180086 http://dx.doi.org/10.1183/13993003.01336-2022 |
Ejemplares similares
-
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)
por: Sebastian, M., et al.
Publicado: (2022) -
Impaired male fertility and abnormal epididymal epithelium differentiation in mice lacking CRISP1 and CRISP4
por: Carvajal, Guillermo, et al.
Publicado: (2018) -
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts
por: Chouaid, Christos, et al.
Publicado: (2022) -
Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms
por: Griesinger, Frank, et al.
Publicado: (2018) -
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting
por: Kraskowski, Oliver, et al.
Publicado: (2023)